Abstract

Despite the introduction of many novel therapeutics in clinical practice, metastatic renal cell carcinoma (RCC) remains a treatment-resistant cancer. As red and processed meat are considered risk factors for RCC, and a vegetable-rich diet is thought to reduce this risk, research into plant-based therapeutics may provide valuable complementary or alternative therapeutics for the management of RCC. Herein, we present the antiproliferative and antiangiogenic effects of maslinic acid, which occurs naturally in edible plants, particularly in olive fruits, and also in a variety of medicinal plants. Human RCC cell lines (ACHN, Caki-1, and SN12K1), endothelial cells (human umbilical vein endothelial cell line [HUVEC]), and primary cultures of kidney proximal tubular epithelial cells (PTEC) were treated with maslinic acid. Maslinic acid was relatively less toxic to PTEC when compared with RCC under similar experimental conditions. In RCC cell lines, maslinic acid induced a significant reduction in proliferation, proliferating cell nuclear antigen, and colony formation. In HUVEC, maslinic acid induced a significant reduction in capillary tube formation in vitro and vascular endothelial growth factor. This study provides a rationale for incorporating a maslinic acid–rich diet either to reduce the risk of developing kidney cancer or as an adjunct to existing antiangiogenic therapy to improve efficacy.

Highlights

  • Renal cell carcinoma (RCC) is a highly metastatic, heterogeneous disease that is resistant to conventional treatment modalities

  • We explored the anticancer and antiangiogenic effects of maslinic acid in RCC cell lines and endothelial cells, respectively

  • Maslinic acid is toxic to RCC cell lines

Read more

Summary

Introduction

Renal cell carcinoma (RCC) is a highly metastatic, heterogeneous disease that is resistant to conventional treatment modalities. Resistance to therapy continues to be a major challenge in the effective treatment of metastatic RCC patients [3, 4]. About 30% of patients are inherently resistant to TKIs, and the remaining 70% who initially respond to treatment eventually develop resistance [5,6,7]. There is an immense need to Journal of Kidney Cancer and VHL 2017;4(1):. Maslinic Acid Inhibits Proliferation of RCC find novel anticancer agents to combat this deadly disease. The contribution of plant-derived natural products to cancer therapy has been widely acknowledged [8]. The best examples are the taxanes paclitaxel and docetaxel, derived from the genus Taxus [9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call